Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heparan-N-sulfatase (human, recombinant)
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intrathecal, Intravenous
01
Overview
Recombinant human heparan-N-sulfatase (rhHNS) is an investigational enzyme replacement therapy developed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo syndrome type A), a lysosomal storage disorder characterized by deficiency of the enzyme sulfamidase. rhHNS is a recombinant protein designed to replace the deficient endogenous enzyme and degrade accumulated heparan sulfate in affected tissues. Because intravenously administered enzymes do not cross the blood-brain barrier, rhHNS has been formulated for intrathecal administration via a surgically implanted drug delivery device to target central nervous system involvement in MPS IIIA. Clinical studies have shown that intrathecal administration results in appreciable CNS tissue distribution; however, long-term studies indicate that while generally well-tolerated, rhHNS did not slow neurocognitive decline in treated patients[2][3][4][5][6].
- Other names
- recombinant human heparan-N-sulfatase
02
Targets
HS (Heparan sulfate)SGSH (N-sulphoglucosamine sulphohydrolase)
Beyond the preview
Go deeper on heparan-N-sulfatase (human, recombinant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heparan-N-sulfatase (human, recombinant).